Grand Rapids applied for — and was denied — an exemption for its 'Thunderhawks' mascot, and has pushed back against what it ...

Oppenheimer notes that Gilead (GILD) shares are weak today following reports from multiple media outlets that the Health and Human Services ...

JPMorgan says that while the Wall Street Journal’s report on potential Centers for Disease Control and Prevention funding cuts for HIV ...

Gilead Sciences, Inc. today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference on Retroviruses ...

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...

Gilead (NASDAQ:GILD) on Tuesday announced encouraging ... as two once-yearly formulations for pre-exposure prophylaxis (PrEP) in HIV prevention. The company said that the median plasma ...

Gilead Sciences, Inc. today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company's injectable HIV-1 capsid inhibitor, ...

But only 3.5 million take pre-exposure prophylaxis (PrEP), which reduces a person ... found that a yearly injection lenacapavir, made by Gilead Sciences, was “safe and well tolerated”.

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart at only once a year.

Last year, Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a single injection every six months.

Tiering signals where the biggest drop-offs are at a position so that you can determine the most optimal time to draft said position. Players whose impact is essentially the same are bundled ...